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Main Text  45 
Numerous research studies have demonstrated the scope and value of eye 46 
movement recording (EMR). There is now potential for EMR to be helpful in a 47 
range of clinical contexts and it could be developed as a routine part of the 48 
repertoire of clinical investigations offered by the NHS, at least in tertiary centres. 49 
We highlight potential uses and challenges below, as a prelude to further 50 
development and debate. 51 
Diagnosis 52 
EMR in patients with nystagmus is already increasingly used clinically and provides 53 
the only method for identifying the exact waveform[1, 2]. A classic example is 54 
identifying the characteristic accelerating waveform of infantile nystagmus 55 
syndrome (INS), which obviates the need for urgent investigations of newly-56 
diagnosed nystagmus, saving the patients and the NHS time and money. EMR 57 
may also indicate the cause of an abnormal head posture (AHP) and identify the 58 
best option for treatment. For example, an AHP may be adopted to use a null point 59 
in subclinical, previously undiagnosed INS, or to put an eye into adduction if the 60 
patient has latent nystagmus.  61 
However, EMR can help in the management of patients other than those with 62 
nystagmus. Examples include: 63 
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In Parkinson's disease, EMRs of saccades help differentiate between dementia 64 
with Lewy bodies, progressive supranuclear palsy, corticobasal degeneration, and 65 
multiple system atrophy[3]. 66 
EMR will differentiate between Gaucher Disease Type 1 and Type 3[4]. This is 67 
particularly important, as there are different treatment pathways for these patient 68 
groups. Abnormal EMR metrics have also been reported in children with three rare 69 
metabolic diseases: Tyrosinemia III, Niemann Pick C and Morquio syndrome[5, 6] – 70 
potentially allowing treatment to be started earlier in the disease process[6].  71 
In psychiatry, EMR performance on the antisaccade task is affected (see:[7]) and 72 
EMR metrics have been used to classify cases of schizophrenia vs controls with 73 
87-98% accuracy [8] which again may allow earlier and more accurate diagnosis, 74 
with earlier treatment and support. 75 
Screening of at-risk individuals 76 
There is a growing body of evidence that EMR may be useful in the screening of 77 
individuals at risk of disorders including Huntington's[9], Alzheimer’s[10, 11] and 78 
Parkinson's[12] Diseases. 79 
Monitoring of disease progression and of response to treatment 80 
The EMR abnormalities in Niemann Pick C, including curved saccades, increase in 81 
magnitude with disease severity suggesting that these measures would also be 82 
useful in monitoring disease progression. Also, in Parkinson’s Disease, the extent 83 
of EMR abnormalities is related to disease progression[13] and responsiveness to 84 
treatment[14]. 85 
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Although these results are encouraging, it is likely that EMR alone will only rarely, if 86 
ever, be used as the only diagnostic criterion. However diagnostic pathways which 87 
include EMR alongside, for example MR imaging[15], are likely to be shorter and 88 
more accurate. Whilst the individual conditions may be rare, such as the metabolic 89 
disorders, there are a much larger number of patients who present with early or 90 
non-specific difficulties in whom treatable metabolic or neurological disease needs 91 
to be ruled out, and therefore, specialist services that care for many patient groups 92 
may benefit from access to reliable EMR within the NHS. 93 
The objective and quantitative measurement of eye movements has a long history 94 
dating back to the early 20th Century[16]. Early methods were uncomfortable and 95 
invasive, and analysis of the resulting data was time-consuming. However, the 96 
advent of both powerful personal computing and fast video-based recording 97 
systems has led to a step-change in the last 15 years in this technology. EMR has 98 
become standard in a wide range of settings including Consumer Research, 99 
Human-Computer Interaction and Virtual Reality. Alongside this, work on both the 100 
neurophysiology of eye movement control[17] and the detailed study of human eye 101 
movement behaviour[18] means that we can map this visual-motor behaviour onto 102 
the patterns of activity across a well studied and extensive brain network. 103 
Routine recording of eye movements in a specialist clinical setting is now therefore 104 
technically feasible and would provide a sensitive, quantitative and objective 105 
method to aid diagnosis and management for a range of patients. However, despite 106 
this potential benefit as a clinical tool, there are considerable challenges associated 107 
with both introducing eye tracking into clinical practice and making it cost-effective. 108 
We are still some way from having eye tracking hardware that is able to 109 
successfully record the eye movements of every patient, whatever their age and 110 
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level of ability. We need a common suite of behavioural assays that are agreed 111 
upon by the wider community, with normative data[19]. 112 
We would need to identify which groups of staff would carry out the assessments, 113 
what training they would need, and how and by whom the resulting data should be 114 
reported. One model is to develop inbuilt test paradigms and proforma reports that 115 
include normative data, to limit the expertise required by the individual setting up 116 
the test and make EMR accessible to a range of users. However, this highlights the 117 
important issue of expertise in interpreting clinical eye movements. EMR may be 118 
used to look for very specific abnormalities in an individual patient and a targeted 119 
approach (as opposed to a general battery of tests) may be important for efficiency 120 
and to address the key clinical question for that patient, especially for children. The 121 
choice between a targeted or comprehensive approach requires both technical 122 
ability and specific expertise. Training is required, but experience is also important 123 
(as any clinician knows). Currently, there is no training offered and no recognised 124 
training pathway. One possible route is to set up training for eye movement clinical 125 
scientists, which could eventually become registrable with the Health and Care 126 
Professions Council (HCPC). As an example, one of us (CH) is registered with the 127 
HCPC as a ‘Clinical Scientist’ (which is a protected title) with designated expertise 128 
in eye movements (the only one we are aware of). This avenue could be explored 129 
as a way forward to formalise (and regulate) clinical oculomotor expertise. 130 
EMR is already widely used in advertising, the aviation industry, rehabilitation 131 
services, computer gaming and virtual reality equipment. The time has come to 132 
explore how best to deploy this technology to the benefit of patients and the NHS.  133 
 134 
135 
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